Summit Therapeutics has confirmed the departure of its Chief Commercial Officer and several other leaders within its commercial and marketing divisions. These separations occurred in the months leading up to a critical FDA decision for the dr-g ivonescimab. The company stated that fewer than five employees were affected in the ordinary course of business. All commercial operations will now report to the chief operating officer and chief financial officer.
Boston, MA
https://www.fiercepharma.com/pharma/summits-commercial-and-market-leadership-gaps-pdufa-decision-looms